Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1991-5-6
|
| pubmed:abstractText |
Fifty patients with intermediate- or high-grade non-Hodgkin's lymphoma (NHL) who had relapsed after a complete remission induced by an Adriamycin-containing chemotherapy regimen participated in this prospective pilot study. The patients ranged in age from 16 to 60 years (median 42 years). All patients received dexamethasone, high-dose cytarabine, and cisplatin (DHAP) for two courses at 3- to 4-week intervals. Patients achieving a partial or complete response were scheduled to receive involved-field radiotherapy and high-dose carmustine, etoposide, cytarabine, and cyclophosphamide (BEAC), followed by autologous bone marrow transplantation (ABMT). Among 48 evaluable patients (ie, 1 was lost to follow-up and 1 had no measurable disease) 7 patients obtained a complete response (CR) and another 21 patients achieved partial response (PR), whereas the remaining 20 patients failed. One responder died of treatment-related toxicity, and six others declined ABMT. The patient with no measurable disease did not progress on DHAP and was submitted to ABMT. Twenty-two patients underwent ABMT [20 with BEAC and 2 with cyclophosphamide plus total body irradiation (TBI)] of whom 2 (9%) died of toxicity and 10 relapsed. One patient was a suicide at 28 months post-ABMT in CCR and 9 are alive disease-free 24 months to 32 months (median 30 months) post-ABMT. The actuarial 2-year event-free survival for patients undergoing transplantation is 40%. This prospective multicenter trial documents the ability of DHAP followed by ABMT to produce durable complete remission in a significant proportion of patients with relapsed aggressive NHL. Forty-four percent of all patients with relapsed lymphoma who entered the study actually underwent ABMT and 20% of the total group are projected to be long-term disease-free survivors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
77
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
1587-92
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2009374-Adolescent,
pubmed-meshheading:2009374-Adult,
pubmed-meshheading:2009374-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:2009374-Bone Marrow Transplantation,
pubmed-meshheading:2009374-Cisplatin,
pubmed-meshheading:2009374-Combined Modality Therapy,
pubmed-meshheading:2009374-Cytarabine,
pubmed-meshheading:2009374-Dexamethasone,
pubmed-meshheading:2009374-Drug Administration Schedule,
pubmed-meshheading:2009374-Europe,
pubmed-meshheading:2009374-Female,
pubmed-meshheading:2009374-Humans,
pubmed-meshheading:2009374-Lymphoma, Non-Hodgkin,
pubmed-meshheading:2009374-Male,
pubmed-meshheading:2009374-Middle Aged,
pubmed-meshheading:2009374-Pilot Projects,
pubmed-meshheading:2009374-Radiotherapy,
pubmed-meshheading:2009374-Transplantation, Autologous
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.
|
| pubmed:affiliation |
Bone Marrow Transplant Department, Centre Leon Berard, Lyon, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|